Why the study?
Do antiarrhythmic drugs (procainamide, propafenone, sotalol) terminate experimental atrial fibrillation by altering refractoriness and wavelength for reentry in anesthetized dogs?
Population
Anesthetized, open-chest dogs with sustained cholinergic atrial fibrillation
Comparison
Class Ia, Ic, and III antiarrhythmic drugs… vs Drug-free conditions
Design
Preclinical
Authors
Loading...
No immediate change to clinical AAD use; extends reentry wavelength mechanism in canine AF but leaves open human translation.
Do antiarrhythmic drugs (procainamide, propafenone, sotalol) terminate experimental atrial fibrillation by altering refractoriness and wavelength for reentry in anesthetized dogs?
Antiarrhythmic drugs terminate experimental atrial fibrillation by increasing the wavelength for reentry at rapid rates, with use-dependent effects on refractoriness determining their efficacy.
Wang et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: